Niclosamide is an old antiparasitic with documented anticancer activity in laboratory models, but its clinical use for cancer has been limited by poor solubility and bioavailability. The authors ...

The BDNF mimetic compound 7,8-dihydroxyflavone (7,8-DHF), a potent small molecular TrkB agonist, displays prominent therapeutic efficacy against Alzheimer’s disease (AD). However, 7,8-DHF has only ...

Solid tumors are notoriously difficult to treat and often put children into a high-risk category as tumors like neuroblastoma, Ewing sarcoma, and rhabdomyosarcoma in these patients often don’t respond ...

Please provide your email address to receive an email when new articles are posted on . Using a machine learning approach, researchers found that patients on selective serotonin reuptake inhibitors ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how branched glycopolymer prodrug-derived nanoassembly combined with a STING agonist activates an immuno-supportive status to ...

The effort to increase the number of druggable targets has coincided with a substantial expansion of the chemical property space in which new drug candidates can reside. As a consequence, contemporary ...

Travis Mickle, CEO of KemPharm, talks about his company’s use of prodrugs, the business opportunities prodrugs represent, and how prodrugs are helping to improve patient centricity. The ...

The current interest in prodrugs is evident. Since 2008, the FDA has approved over 30 prodrugs, and approximately 10% of all marketed drugs worldwide can be considered prodrugs. Consequently, the ...

A team of scientists from the United States has recently investigated the efficacy of an anti-inflammatory prodrug Minnelide in treating coronavirus disease 2019 (COVID-19), a disease caused by severe ...

Unlike conventional cancer drugs that attack and kill cancer cells directly, anti-cancer immunotherapy, which kills cancer cells by strengthening the body's immunity, is a novel type of cancer ...

Johns Hopkins Medicine researchers have revamped an anti-cancer drug to better target cancer cells and leave healthy tissues unharmed. Scientists have dubbed this type of targeted approach a “prodrug” ...